Who are Prothena Corporation plc's main suppliers?

Prothena Corporation plc (PRTA) key suppliers include: ROCHE, Inhibikase Therapeutics, Inc., NOVO-NORDISK. View the full supplier network at chainsifter.com/chain/PRTA.

Who are Prothena Corporation plc's major customers?

Prothena Corporation plc (PRTA) key customers include: NOVO-NORDISK, Inhibikase Therapeutics, Inc., Novo Nordisk A/S, Novo Nordisk A/S, Perrigo Company plc and 8 more. View the full customer network at chainsifter.com/chain/PRTA.

What sector is Prothena Corporation plc in?

Prothena Corporation plc (PRTA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Prothena Corporation plc Supplier List (PRTA): 3 Verified Suppliers

3Suppliers

13Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Prothena Corporation plc (PRTA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

2Distinct source URLs

4High confidence

0.714Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Prothena Corporation plc Suppliers

Ticker	Name	Confidence	Evidence
ROCHE	ROCHE	90%	We have entered into the License Agreement with Roche for the development of prasinezumab
IKT	Inhibikase Therapeutics, Inc.	72%	Reciprocal relationship from IKT graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT grap…
NOVO-NORDISK	NOVO-NORDISK	60%	we may enter into additional agreements in the future, and we might not realize the anticipated benefits of such agreements including receiving anticipated milestone payments pursuant to these agreements

Prothena Corporation plc Customers

Ticker	Name	Confidence	Evidence
NOVO-NORDISK	NOVO-NORDISK	90%	The Company’s revenue during the three months ended March 31, 2026 was primarily from revenue from the development milestone payment received from Novo Nordisk
IKT	Inhibikase Therapeutics, Inc.	72%	Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obta…
NVO	Novo Nordisk A/S	72%	nted cash flow model used to determine the best estimate of selling price for the license included the market opportunity for commercialization of PRX019, the probability of successfully developing/c…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from NVO graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from NVO grap…
PRGO	Perrigo Company plc	72%	Reciprocal relationship from PRGO graph: Reciprocal relationship from PRTA graph: scientific and other personnel are critical to our growth and future success. Competition for qualified personnel in …
PRGO	Perrigo Company plc	72%	scientific and other personnel are critical to our growth and future success. Competition for qualified personnel in our industry is intense. We may not be able to attract and retain these personnel …
BIOSCIENCES-LIMITED	BIOSCIENCES-LIMITED	62%	s us to make estimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures. There were no significant changes to our critical accounting polici…
CELGENE-SWITZERLAND-LLC	CELGENE-SWITZERLAND-LLC	62%	believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2024, and 2023. Other Co…
F-HOFFMANN-LA-ROCHE-LTD	F-HOFFMANN-LA-ROCHE-LTD	62%	believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2024, and 2023. Other Co…
HOFFMANN-LA-ROCHE-INC	HOFFMANN-LA-ROCHE-INC	62%	believes the estimated fair value of these indemnification agreements is minimal. Accordingly, the Company had no liabilities recorded for these agreements as of December 31, 2024, and 2023. Other Co…
NEOTOPE-NEUROSCIENCE-LIMITED	NEOTOPE-NEUROSCIENCE-LIMITED	62%	nted cash flow model used to determine the best estimate of selling price for the license included the market opportunity for commercialization of PRX019, the probability of successfully developing/c…
PROTHENA-BIOSCIENCES-INC	PROTHENA-BIOSCIENCES-INC	62%	e agreements as of March 31, 2026, and December 31, 2025. Other Commitments In the normal course of business, the Company enters into various firm purchase commitments primarily related to research a…
PROTHENA-BIOSCIENCES-LIMITED	PROTHENA-BIOSCIENCES-LIMITED	62%	e agreements as of March 31, 2026, and December 31, 2025. Other Commitments In the normal course of business, the Company enters into various firm purchase commitments primarily related to research a…

Prothena Corporation plc Debt Obligations

Instrument	Description	Confidence	Evidence
PRTA-DEBT	Debt stack $7.7M	90%	Market cache reports total debt of $7.7M.

Prothena Corporation plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Prothena Corporation plc.

Prothena Corporation plc Ownership

Holder	Name	Confidence	Evidence
PRTA-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 187 tracked holders.

Prothena Corporation plc Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
HIMS	Hims & Hers Health, Inc.	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
IPHA	Innate Pharma S.A.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
NONOF	Novo Nordisk A/S	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
SLGN	Silgan Holdings Inc.	100.00	2
ASND	Ascendis Pharma A/S	100.00	2
EVAX	Evaxion A/S	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
IKT	Inhibikase Therapeutics, Inc.	100.00	1	['customer', 'supplier']
LLY	Eli Lilly and Company	100.00	2
CVS	CVS Health Corporation	50.00	2
ORANY	ORANGE	50.00	2
GYRE	Gyre Therapeutics, Inc.	50.00	2
GOSS	Gossamer Bio, Inc.	50.00	2
KR	The Kroger Co.	50.00	2
DNLI	Denali Therapeutics Inc.	50.00	2
KRRO	Korro Bio, Inc.	50.00	2
MDGL	Madrigal Pharmaceuticals, Inc.	50.00	2

Prothena Corporation plc Supply Chain